Molecular virology of Kaposi's sarcoma-associated herpesvirus.
PDF (5.2M)
Journal: 2001/July - Philosophical Transactions of the Royal Society B: Biological Sciences
ISSN: 0962-8436
Abstract:
Kaposi's sarcoma-associated herpesvirus (KSHV), the most recently discovered human tumour virus, is the causative agent of Kaposi's sarcoma, primary effusion lymphoma and some forms of Castleman's disease. KSHV is a rhadinovirus, and like other rhadinoviruses, it has an extensive array of regulatory genes obtained from the host cell genome. These pirated KSHV proteins include homologues to cellular CD21, three different beta-chemokines, IL-6, BCL-2, several different interferon regulatory factor homologues, Fas-ligand ICE inhibitory protein (FLIP), cyclin D and a G-protein-coupled receptor, as well as DNA synthetic enzymes including thymidylate synthase, dihydrofolate reductase, DNA polymerase, thymidine kinase and ribonucleotide reductases. Despite marked differences between KSHV and Epstein-Barr virus, both viruses target many of the same cellular pathways, but use different strategies to achieve the same effects. KSHV proteins have been identified which inhibit cell-cycle regulation checkpoints, apoptosis control mechanisms and the immune response regulatory machinery. Inhibition of these cellular regulatory networks app ears to be a defensive means of allowing the virus to escape from innate antiviral immune responses. However, due to the overlapping nature of innate immune and tumour-suppressor pathways, inhibition of these regulatory networks can lead to unregulated cell proliferation and may contribute to virus-induced tumorigenesis.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(58)
References
(144)
Diseases
(1)
Chemicals
(1)
Organisms
(4)
Processes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Philos Trans R Soc Lond B Biol Sci 356(1408): 499-516
PMID: 11313008

Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), the most recently discovered human tumour virus, is the causative agent of Kaposi's sarcoma, primary effusion lymphoma and some forms of Castleman's disease. KSHV is a rhadinovirus, and like other rhadinoviruses, it has an extensive array of regulatory genes obtained from the host cell genome. These pirated KSHV proteins include homologues to cellular CD21, three different beta-chemokines, IL-6, BCL-2, several different interferon regulatory factor homologues, Fas-ligand ICE inhibitory protein (FLIP), cyclin D and a G-protein-coupled receptor, as well as DNA synthetic enzymes including thymidylate synthase, dihydrofolate reductase, DNA polymerase, thymidine kinase and ribonucleotide reductases. Despite marked differences between KSHV and Epstein-Barr virus, both viruses target many of the same cellular pathways, but use different strategies to achieve the same effects. KSHV proteins have been identified which inhibit cell-cycle regulation checkpoints, apoptosis control mechanisms and the immune response regulatory machinery. Inhibition of these cellular regulatory networks app ears to be a defensive means of allowing the virus to escape from innate antiviral immune responses. However, due to the overlapping nature of innate immune and tumour-suppressor pathways, inhibition of these regulatory networks can lead to unregulated cell proliferation and may contribute to virus-induced tumorigenesis.

Full Text

The Full Text of this article is available as a PDF (5.2M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, Früh K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997 May;6(5):613–621. [PubMed] [Google Scholar]
  • Albrecht JC, Nicholas J, Biller D, Cameron KR, Biesinger B, Newman C, Wittmann S, Craxton MA, Coleman H, Fleckenstein B, et al. Primary structure of the herpesvirus saimiri genome. J Virol. 1992 Aug;66(8):5047–5058.[PMC free article] [PubMed] [Google Scholar]
  • Ambroziak JA, Blackbourn DJ, Herndier BG, Glogau RG, Gullett JH, McDonald AR, Lennette ET, Levy JA. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science. 1995 Apr 28;268(5210):582–583. [PubMed] [Google Scholar]
  • Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999 Jun 15;93(12):4034–4043. [PubMed] [Google Scholar]
  • Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 1996 Oct 1;88(7):2648–2654. [PubMed] [Google Scholar]
  • Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature. 1997 Jan 23;385(6614):347–350. [PubMed] [Google Scholar]
  • Asou H, Said JW, Yang R, Munker R, Park DJ, Kamada N, Koeffler HP. Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood. 1998 Apr 1;91(7):2475–2481. [PubMed] [Google Scholar]
  • Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997 Jun 27;89(7):1175–1184. [PubMed] [Google Scholar]
  • Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998 Jan 1;391(6662):86–89. [PubMed] [Google Scholar]
  • Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999 Apr 23;284(5414):641–644. [PubMed] [Google Scholar]
  • Benelli R, Barbero A, Buffa A, Aluigi MG, Masiello L, Morbidelli L, Ziche M, Albini A, Noonan D. Distinct chemotactic and angiogenic activities of peptides derived from Kaposi's sarcoma virus encoded chemokines. Int J Oncol. 2000 Jul;17(1):75–81. [PubMed] [Google Scholar]
  • Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990 Jan 20;335(8682):123–128. [PubMed] [Google Scholar]
  • Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172–1176.[PMC free article] [PubMed] [Google Scholar]
  • Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature. 1996 Sep 26;383(6598):344–347. [PubMed] [Google Scholar]
  • Boshoff C, Weiss RA. Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res. 1998;75:57–86. [PubMed] [Google Scholar]
  • Brander C, Suscovich T, Lee Y, Nguyen PT, O'Connor P, Seebach J, Jones NG, van Gorder M, Walker BD, Scadden DT. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol. 2000 Aug 15;165(4):2077–2083. [PubMed] [Google Scholar]
  • Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol. 1999 Aug 15;163(4):2017–2022. [PubMed] [Google Scholar]
  • Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood. 1998 Mar 15;91(6):1858–1863. [PubMed] [Google Scholar]
  • Burýsek L, Yeow WS, Lubyová B, Kellum M, Schafer SL, Huang YQ, Pitha PM. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol. 1999 Sep;73(9):7334–7342.[PMC free article] [PubMed] [Google Scholar]
  • Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol. 1999 Jun;73(6):4786–4793.[PMC free article] [PubMed] [Google Scholar]
  • Cannon JS, Nicholas J, Orenstein JM, Mann RB, Murray PG, Browning PJ, DiGiuseppe JA, Cesarman E, Hayward GS, Ambinder RF. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis. 1999 Sep;180(3):824–828. [PubMed] [Google Scholar]
  • Cannon MJ, Flanders WD, Pellett PE. Occurrence of primary cancers in association with multiple myeloma and Kaposi's sarcoma in the United States, 1973-1995. Int J Cancer. 2000 Feb 15;85(4):453–456. [PubMed] [Google Scholar]
  • Carbone A, Gloghini A, Bontempo D, Monini P, Tirelli U, Volpe R, Browning PJ, Gaidano G. Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1). Am J Pathol. 2000 Apr;156(4):1209–1215.[PMC free article] [PubMed] [Google Scholar]
  • Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995 May 4;332(18):1186–1191. [PubMed] [Google Scholar]
  • Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 1995 Oct 1;86(7):2708–2714. [PubMed] [Google Scholar]
  • Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol. 1996 Nov;70(11):8218–8223.[PMC free article] [PubMed] [Google Scholar]
  • Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med. 2000 Feb 7;191(3):417–422.[PMC free article] [PubMed] [Google Scholar]
  • Chang J, Ganem D. On the control of late gene expression in Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol. 2000 Aug;81(Pt 8):2039–2047. [PubMed] [Google Scholar]
  • Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865–1869. [PubMed] [Google Scholar]
  • Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden-Kent, Paterson H, Weiss RA, Mittnacht S. Cyclin encoded by KS herpesvirus. Nature. 1996 Aug 1;382(6590):410–410. [PubMed] [Google Scholar]
  • Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene. 1999 Oct 14;18(42):5738–5746. [PubMed] [Google Scholar]
  • Cheng EH, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, Hardwick JM. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690–694.[PMC free article] [PubMed] [Google Scholar]
  • Choi JK, Lee BS, Shim SN, Li M, Jung JU. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J Virol. 2000 Jan;74(1):436–446.[PMC free article] [PubMed] [Google Scholar]
  • Cinquina CC, Grogan E, Sun R, Lin SF, Beardsley GP, Miller G. Dihydrofolate reductase from Kaposi's sarcoma-associated herpesvirus. Virology. 2000 Mar 1;268(1):201–217. [PubMed] [Google Scholar]
  • Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051–8056.[PMC free article] [PubMed] [Google Scholar]
  • Cotter MA, 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology. 1999 Nov 25;264(2):254–264. [PubMed] [Google Scholar]
  • Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569–21574. [PubMed] [Google Scholar]
  • DeBruyne LA, Li K, Bishop DK, Bromberg JS. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 2000 Apr;7(7):575–582. [PubMed] [Google Scholar]
  • Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol. 1998 Oct;72(10):8309–8315.[PMC free article] [PubMed] [Google Scholar]
  • Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546–4551.[PMC free article] [PubMed] [Google Scholar]
  • Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA, Lu X, Mittnacht S. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J. 1999 Feb 1;18(3):644–653.[PMC free article] [PubMed] [Google Scholar]
  • Endres MJ, Garlisi CG, Xiao H, Shan L, Hedrick JA. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. J Exp Med. 1999 Jun 21;189(12):1993–1998.[PMC free article] [PubMed] [Google Scholar]
  • Fiorelli V, Gendelman R, Sirianni MC, Chang HK, Colombini S, Markham PD, Monini P, Sonnabend J, Pintus A, Gallo RC, et al. gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood. 1998 Feb 1;91(3):956–967. [PubMed] [Google Scholar]
  • Flowers CC, Flowers SP, Nabel GJ. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor confers resistance to the antiproliferative effect of interferon-alpha. Mol Med. 1998 Jun;4(6):402–412.[PMC free article] [PubMed] [Google Scholar]
  • Friborg J, Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999 Dec 23;402(6764):889–894. [PubMed] [Google Scholar]
  • Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med. 1996 Jul 25;335(4):233–241. [PubMed] [Google Scholar]
  • Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996 Aug;2(8):925–928. [PubMed] [Google Scholar]
  • Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene. 1997 Oct 16;15(16):1979–1985. [PubMed] [Google Scholar]
  • Geras-Raaka E, Arvanitakis L, Bais C, Cesarman E, Mesri EA, Gershengorn MC. Inhibition of constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in culture. J Exp Med. 1998 Mar 2;187(5):801–806.[PMC free article] [PubMed] [Google Scholar]
  • Geras-Raaka E, Varma A, Clark-Lewis I, Gershengorn MC. Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor. Biochem Biophys Res Commun. 1998 Dec 30;253(3):725–727. [PubMed] [Google Scholar]
  • Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest. 1998 Oct 15;102(8):1469–1472.[PMC free article] [PubMed] [Google Scholar]
  • Glenn M, Rainbow L, Auradé F, Davison A, Schulz TF. Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol. 1999 Aug;73(8):6953–6963.[PMC free article] [PubMed] [Google Scholar]
  • Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, Weiss RA, Mittnacht S. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997 Jun;71(6):4193–4198.[PMC free article] [PubMed] [Google Scholar]
  • Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000 Jul 1;14(13):1553–1577. [PubMed] [Google Scholar]
  • Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C, Miller G. Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol. 2000 Jul;74(13):6207–6212.[PMC free article] [PubMed] [Google Scholar]
  • Gruffat H, Portes-Sentis S, Sergeant A, Manet E. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) encodes a homologue of the Epstein-Barr virus bZip protein EB1. J Gen Virol. 1999 Mar;80(Pt 3):557–561. [PubMed] [Google Scholar]
  • Hammarskjöld ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol. 1992 Nov;66(11):6496–6501.[PMC free article] [PubMed] [Google Scholar]
  • Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 1993 Feb 12;259(5097):971–974. [PubMed] [Google Scholar]
  • Hibbitts S, Reeves JD, Simmons G, Gray PW, Epstein LG, Schols D, de Clercq E, Wells TN, Proudfoot AE, Clapham PR. Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):989–1000. [PubMed] [Google Scholar]
  • Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995 Jun 1;375(6530):411–415. [PubMed] [Google Scholar]
  • Ho HH, Du D, Gershengorn MC. The N terminus of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity. J Biol Chem. 1999 Oct 29;274(44):31327–31332. [PubMed] [Google Scholar]
  • Hobeika AC, Subramaniam PS, Johnson HM. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene. 1997 Mar 13;14(10):1165–1170. [PubMed] [Google Scholar]
  • Hoischen SH, Vollmer P, März P, Ozbek S, Götze KS, Peschel C, Jostock T, Geib T, Müllberg J, Mechtersheimer S, et al. Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem. 2000 Jun;267(12):3604–3612. [PubMed] [Google Scholar]
  • Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem. 1997 Apr 11;272(15):9621–9624. [PubMed] [Google Scholar]
  • Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10;388(6638):190–195. [PubMed] [Google Scholar]
  • Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000 Jun;74(11):5300–5309.[PMC free article] [PubMed] [Google Scholar]
  • Jacobson RH, Ladurner AG, King DS, Tjian R. Structure and function of a human TAFII250 double bromodomain module. Science. 2000 May 26;288(5470):1422–1425. [PubMed] [Google Scholar]
  • Jayachandra S, Low KG, Thlick AE, Yu J, Ling PD, Chang Y, Moore PS. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11566–11571.[PMC free article] [PubMed] [Google Scholar]Retracted
  • Jonak GJ, Knight E., Jr Selective reduction of c-myc mRNA in Daudi cells by human beta interferon. Proc Natl Acad Sci U S A. 1984 Mar;81(6):1747–1750.[PMC free article] [PubMed] [Google Scholar]
  • Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood. 1999 Oct 15;94(8):2871–2879. [PubMed] [Google Scholar]
  • Judde JG, Lacoste V, Brière J, Kassa-Kelembho E, Clyti E, Couppié P, Buchrieser C, Tulliez M, Morvan J, Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst. 2000 May 3;92(9):729–736. [PubMed] [Google Scholar]
  • Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology. 2000 Apr 10;269(2):335–344. [PubMed] [Google Scholar]
  • Kirshner JR, Staskus K, Haase A, Lagunoff M, Ganem D. Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J Virol. 1999 Jul;73(7):6006–6014.[PMC free article] [PubMed] [Google Scholar]
  • Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Lüttichau HR, Gerstoft J, Clapham PR, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656–1659. [PubMed] [Google Scholar]
  • Kwok RP, Laurance ME, Lundblad JR, Goldman PS, Shih H, Connor LM, Marriott SJ, Goodman RH. Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature. 1996 Apr 18;380(6575):642–646. [PubMed] [Google Scholar]
  • Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5704–5709.[PMC free article] [PubMed] [Google Scholar]
  • Lee BS, Alvarez X, Ishido S, Lackner AA, Jung JU. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1. J Exp Med. 2000 Jul 3;192(1):11–21.[PMC free article] [PubMed] [Google Scholar]
  • Lee H, Guo J, Li M, Choi JK, DeMaria M, Rosenzweig M, Jung JU. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol. 1998 Sep;18(9):5219–5228.[PMC free article] [PubMed] [Google Scholar]
  • Lee H, Veazey R, Williams K, Li M, Guo J, Neipel F, Fleckenstein B, Lackner A, Desrosiers RC, Jung JU. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med. 1998 Apr;4(4):435–440. [PubMed] [Google Scholar]
  • Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, Jung JU. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol. 1997 Mar;71(3):1984–1991.[PMC free article] [PubMed] [Google Scholar]
  • Li M, Lee H, Guo J, Neipel F, Fleckenstein B, Ozato K, Jung JU. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol. 1998 Jul;72(7):5433–5440.[PMC free article] [PubMed] [Google Scholar]
  • Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997 Jun 19;387(6635):823–827. [PubMed] [Google Scholar]
  • Lin SF, Robinson DR, Miller G, Kung HJ. Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus. J Virol. 1999 Mar;73(3):1909–1917.[PMC free article] [PubMed] [Google Scholar]
  • Ludlow JW, Skuse GR. Viral oncoprotein binding to pRB, p107, p130, and p300. Virus Res. 1995 Feb;35(2):113–121. [PubMed] [Google Scholar]
  • Lukac DM, Renne R, Kirshner JR, Ganem D. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology. 1998 Dec 20;252(2):304–312. [PubMed] [Google Scholar]
  • Lukac DM, Kirshner JR, Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol. 1999 Nov;73(11):9348–9361.[PMC free article] [PubMed] [Google Scholar]
  • Mahoney SE, Duvic M, Nickoloff BJ, Minshall M, Smith LC, Griffiths CE, Paddock SW, Lewis DE. Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions. J Clin Invest. 1991 Jul;88(1):174–185.[PMC free article] [PubMed] [Google Scholar]
  • Mann DJ, Child ES, Swanton C, Laman H, Jones N. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J. 1999 Feb 1;18(3):654–663.[PMC free article] [PubMed] [Google Scholar]
  • Mittnacht S, Boshoff C. Viral cyclins. Rev Med Virol. 2000 May-Jun;10(3):175–184. [PubMed] [Google Scholar]
  • Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell. 1988 Sep 9;54(6):903–913. [PubMed] [Google Scholar]
  • Moore PS, Chang Y. Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet. 1998 Apr;14(4):144–150. [PubMed] [Google Scholar]
  • Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996 Dec 6;274(5293):1739–1744. [PubMed] [Google Scholar]
  • Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol. 1996 Jan;70(1):549–558.[PMC free article] [PubMed] [Google Scholar]
  • Müllberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N, Heinz D, Galle PR, Klouche M, Rose-John S. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol. 2000 May 1;164(9):4672–4677. [PubMed] [Google Scholar]
  • Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE, Fleckenstein B. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997 Jan;71(1):839–842.[PMC free article] [PubMed] [Google Scholar]
  • Neipel F, Albrecht JC, Fleckenstein B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol. 1997 Jun;71(6):4187–4192.[PMC free article] [PubMed] [Google Scholar]
  • Neipel F, Albrecht JC, Fleckenstein B. Human herpesvirus 8--the first human Rhadinovirus. J Natl Cancer Inst Monogr. 1998;(23):73–77. [PubMed] [Google Scholar]
  • Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol. 1993 Jan;13(1):588–599.[PMC free article] [PubMed] [Google Scholar]
  • Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan X, Ciufo D, Hendrickson SB, Guo HG, Hayward GS, Reitz MS. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997 Mar;3(3):287–292. [PubMed] [Google Scholar]
  • Ojala PM, Tiainen M, Salven P, Veikkola T, Castaños-Vélez E, Sarid R, Biberfeld P, Mäkelä TP. Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res. 1999 Oct 1;59(19):4984–4989. [PubMed] [Google Scholar]
  • Olsen SJ, Tarte K, Sherman W, Hale EE, Weisse MT, Orazi A, Klein B, Chang Y. Evidence against KSHV infection in the pathogenesis of multiple myeloma. Virus Res. 1998 Oct;57(2):197–202. [PubMed] [Google Scholar]
  • Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein MD, Ganem D, Herndier B. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS. 1997 Apr;11(5):F35–F45. [PubMed] [Google Scholar]
  • Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol. 1999 Oct;60(10):921–927. [PubMed] [Google Scholar]
  • Parravicini C, Corbellino M, Paulli M, Magrini U, Lazzarino M, Moore PS, Chang Y. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol. 1997 Dec;151(6):1517–1522.[PMC free article] [PubMed] [Google Scholar]
  • Parravicini C, Lauri E, Baldini L, Neri A, Poli F, Sirchia G, Moroni M, Galli M, Corbellino M. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science. 1997 Dec 12;278(5345):1969–1973. [PubMed] [Google Scholar]
  • Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000 Mar;156(3):743–749.[PMC free article] [PubMed] [Google Scholar]
  • Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999 Sep 15;18(18):5061–5072.[PMC free article] [PubMed] [Google Scholar]
  • Pica F, Volpi A, Serafino A, Fraschetti M, Franzese O, Garaci E. Autocrine nerve growth factor is essential for cell survival and viral maturation in HHV-8-infected primary effusion lymphoma cells. Blood. 2000 May 1;95(9):2905–2912. [PubMed] [Google Scholar]
  • Platt GM, Cannell E, Cuomo ME, Singh S, Mittnacht S. Detection of the human herpesvirus 8-encoded cyclin protein in primary effusion lymphoma-derived cell lines. Virology. 2000 Jul 5;272(2):257–266. [PubMed] [Google Scholar]
  • Ploegh HL. Viral strategies of immune evasion. Science. 1998 Apr 10;280(5361):248–253. [PubMed] [Google Scholar]
  • Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996 Mar;2(3):342–346. [PubMed] [Google Scholar]
  • Rettig MB, Ma HJ, Vescio RA, Põld M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1997 Jun 20;276(5320):1851–1854. [PubMed] [Google Scholar]
  • Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001 Jan;75(1):429–438.[PMC free article] [PubMed] [Google Scholar]
  • Roan F, Zimring JC, Goodbourn S, Offermann MK. Transcriptional activation by the human herpesvirus-8-encoded interferon regulatory factor. J Gen Virol. 1999 Aug;80(Pt 8):2205–2209. [PubMed] [Google Scholar]
  • Rosenkilde MM, Kledal TN, Bräuner-Osborne H, Schwartz TW. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem. 1999 Jan 8;274(2):956–961. [PubMed] [Google Scholar]
  • Sangfelt O, Erickson S, Einhorn S, Grandér D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene. 1997 Jan 30;14(4):415–423. [PubMed] [Google Scholar]
  • Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med. 1997 Mar;3(3):293–298. [PubMed] [Google Scholar]
  • Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998 Feb;72(2):1005–1012.[PMC free article] [PubMed] [Google Scholar]
  • Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res. 1999;52:139–232. [PubMed] [Google Scholar]
  • Sarid R, Wiezorek JS, Moore PS, Chang Y. Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol. 1999 Feb;73(2):1438–1446.[PMC free article] [PubMed] [Google Scholar]
  • Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J Antimicrob Chemother. 2000 Apr;45 (Suppl T3):15–27. [PubMed] [Google Scholar]
  • Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res. 1995 Jun 1;55(11):2262–2265. [PubMed] [Google Scholar]
  • Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995 Aug 15;86(4):1276–1280. [PubMed] [Google Scholar]
  • Sozzani S, Luini W, Bianchi G, Allavena P, Wells TN, Napolitano M, Bernardini G, Vecchi A, D'Ambrosio D, Mazzeo D, et al. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood. 1998 Dec 1;92(11):4036–4039. [PubMed] [Google Scholar]
  • Staskus KA, Sun R, Miller G, Racz P, Jaslowski A, Metroka C, Brett-Smith H, Haase AT. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999 May;73(5):4181–4187.[PMC free article] [PubMed] [Google Scholar]
  • Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VL, Endo Y, Sasaki T, Simmons G, Boshoff C, et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood. 2000 Feb 15;95(4):1151–1157. [PubMed] [Google Scholar]
  • Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol. 1999 Mar;73(3):2232–2242.[PMC free article] [PubMed] [Google Scholar]
  • Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997 Nov 13;390(6656):184–187. [PubMed] [Google Scholar]
  • Swanton C, Card GL, Mann D, McDonald N, Jones N. Overcoming inhibitions: subversion of CKI function by viral cyclins. Trends Biochem Sci. 1999 Mar;24(3):116–120. [PubMed] [Google Scholar]
  • Talbot SJ, Weiss RA, Kellam P, Boshoff C. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology. 1999 Apr 25;257(1):84–94. [PubMed] [Google Scholar]
  • Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, Aizawa S, Tokino T, Oren M, Taniguchi T. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature. 1996 Aug 29;382(6594):816–818. [PubMed] [Google Scholar]
  • Taniguchi T, Harada H, Lamphier M. Regulation of the interferon system and cell growth by the IRF transcription factors. J Cancer Res Clin Oncol. 1995;121(9-10):516–520. [PubMed] [Google Scholar]
  • Taniguchi T, Lamphier MS, Tanaka N. IRF-1: the transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta. 1997 Aug 8;1333(1):M9–17. [PubMed] [Google Scholar]
  • Tarte K, Olsen SJ, Yang Lu Z, Legouffe E, Rossi JF, Chang Y, Klein B. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood. 1998 Mar 15;91(6):1852–1857. [PubMed] [Google Scholar]
  • Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997 Apr 3;386(6624):517–521. [PubMed] [Google Scholar]
  • Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood. 1997 Jul 1;90(1):279–289. [PubMed] [Google Scholar]
  • Wan X, Wang H, Nicholas J. Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol. 1999 Oct;73(10):8268–8278.[PMC free article] [PubMed] [Google Scholar]
  • Wang L, Grossman SR, Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):430–435.[PMC free article] [PubMed] [Google Scholar]
  • Weisz A, Kirchhoff S, Levi BZ. IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters. Int Immunol. 1994 Aug;6(8):1125–1131. [PubMed] [Google Scholar]
  • Whitby D, Boshoff C, Luppi M, Torelli G. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science. 1997 Dec 12;278(5345):1971–1973. [PubMed] [Google Scholar]
  • Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 1996 Jul 25;382(6589):319–324. [PubMed] [Google Scholar]
  • Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641–6646.[PMC free article] [PubMed] [Google Scholar]
  • Zhu FX, Cusano T, Yuan Y. Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol. 1999 Jul;73(7):5556–5567.[PMC free article] [PubMed] [Google Scholar]
  • Zimring JC, Goodbourn S, Offermann MK. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol. 1998 Jan;72(1):701–707.[PMC free article] [PubMed] [Google Scholar]
School of Public Health and Department of Pathology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. psm9@columbia.edu
School of Public Health and Department of Pathology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. psm9@columbia.edu
Copyright notice

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), the most recently discovered human tumour virus, is the causative agent of Kaposi's sarcoma, primary effusion lymphoma and some forms of Castleman's disease. KSHV is a rhadinovirus, and like other rhadinoviruses, it has an extensive array of regulatory genes obtained from the host cell genome. These pirated KSHV proteins include homologues to cellular CD21, three different beta-chemokines, IL-6, BCL-2, several different interferon regulatory factor homologues, Fas-ligand ICE inhibitory protein (FLIP), cyclin D and a G-protein-coupled receptor, as well as DNA synthetic enzymes including thymidylate synthase, dihydrofolate reductase, DNA polymerase, thymidine kinase and ribonucleotide reductases. Despite marked differences between KSHV and Epstein-Barr virus, both viruses target many of the same cellular pathways, but use different strategies to achieve the same effects. KSHV proteins have been identified which inhibit cell-cycle regulation checkpoints, apoptosis control mechanisms and the immune response regulatory machinery. Inhibition of these cellular regulatory networks app ears to be a defensive means of allowing the virus to escape from innate antiviral immune responses. However, due to the overlapping nature of innate immune and tumour-suppressor pathways, inhibition of these regulatory networks can lead to unregulated cell proliferation and may contribute to virus-induced tumorigenesis.

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.